

Redx Pharma awarded US\$1 million grant by CARB-X

30 Mar 2017

- Redx selected as one of 11 initial candidates after competitive global selection process in recognition of innovative science programs
- Collaborative grant in anti-infectives enables Redx to advance its Gram-negative program with a prospective partner

Redx Pharma is pleased to announce that it has been awarded aUS\$1 million grant by CARB-X, one of the world's largest public-private partnerships, launched in July 2016 to accelerate global antibacterial innovation and research. The 11 successful projects were selected through a competitive process from 168 applications from around the world. The awarded grants were based on the merits of each of the company's research proposals, as evaluated by the CARB-X Advisory Board and the CARB-X team.

Today's announcement by CARB-X showcases the first projects selected for the *Powered byCARB-X* portfolio, spotlighting Redx as a highly-respected partner of choice on a global stage. Redx will receive US\$1 million over 18 months, with an option for future tiered milestone payments, to drive scientific progress against globally challenging drug resistant Gram-negativebacteria. This collaboration with CARB-X enables Redx to move its Gram-negative program into the next stage of development with a prospective partner.

Dr Neil Murray, Chief Executive Officer of Redx Pharma, said: We are delighted to be collaborating with CARB-X, a truly innovative initiative that is targeting the development of new life-saving antibacterials and diagnostics. Receiving this grant today is testament to the great science that exists at Redx. This grant cements a path forward for our recently announced strategy, to secure external partners to ensure that our high quality anti-infective science will continue whilst we sharpen our focus on the clinical development of our oncology and immunology programs.

CARB-X

Xccelerating global antibacterial innovation